DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes.

DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such als insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization:

1. A small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes).
2. A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes)

DeveloGen is based in Goettingen, Germany.